Horizons of Heparin Therapy in COVID-19 and Pandemic-Related Diseases

Area of Science:

• * Infectious Diseases and Virology
• * Hematology and Thrombosis
• * Pharmacology

Background:

• * Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents with high transmission rates and is increasingly recognized for its vascular dysfunction and thrombotic complications.
• * These thrombotic events are indicative of severe COVID-19, correlating with multiple organ failure and increased mortality, distinguishing it from typical acute respiratory illnesses.
• * Heparin, an anticoagulant, has demonstrated significant efficacy in reducing COVID-19 severity and mortality, attributed to its multifunctional properties.

Purpose of the Study:

• * To review and synthesize existing literature on the pathogenic mechanisms of SARS-CoV-2 infection.
• * To elucidate the properties of heparin that enable it to counteract these pathogenic mechanisms at various stages.
• * To propose a novel hypothesis on SARS-CoV-2 pathogenesis and explore innovative applications of low-dose heparin therapy beyond anticoagulation.

Main Methods:

• * Comprehensive literature review of studies on SARS-CoV-2 pathogenesis and heparin's mechanisms of action.
• * Analysis of clinical data linking thrombotic complications to COVID-19 severity and mortality.
• * Theoretical modeling and hypothesis generation regarding SARS-CoV-2 pathogenesis and heparin's therapeutic potential.

Main Results:

• * COVID-19 pathogenesis involves significant vascular dysfunction and thrombosis, contributing to severe outcomes and mortality.
• * Heparin exhibits multifaceted properties that can inhibit SARS-CoV-2 pathogenic mechanisms.
• * A hypothesis for a 'vicious circle' in SARS-CoV-2 pathogenesis is proposed, suggesting a role for heparin in interrupting this cycle.

Conclusions:

• * Heparin's diverse pharmacological actions offer a promising therapeutic strategy for managing COVID-19, particularly its thrombotic manifestations.
• * Further research into low-dose heparin therapy, leveraging its non-anticoagulant effects, could provide novel treatment avenues for COVID-19.
• * Understanding heparin's interaction with SARS-CoV-2 pathogenesis is crucial for optimizing its clinical application and developing future therapeutic strategies.